SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 866.43 |
| Enterprise Value ($M) | 857.96 |
| Book Value ($M) | 44.09 |
| Book Value / Share | 0.57 |
| Price / Book | 19.65 |
| NCAV ($M) | 20.86 |
| NCAV / Share | 0.27 |
| Price / NCAV | 41.54 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.03 |
| Return on Assets (ROA) | -0.03 |
| Return on Equity (ROE) | -0.03 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 2.82 |
| Current Ratio | 3.39 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 29.77 |
| Assets | 53.00 |
| Liabilities | 8.91 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 25.10 |
| Operating Income | -0.56 |
| Net Income | -1.44 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.54 |
| Cash from Investing | 0.98 |
| Cash from Financing | -0.49 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13D | AIX Inc. | 72.00 | ||
| 13D | LX Management Co Ltd | 49.00 | ||
| 13D/A | Ahanzhai Development Ltd | 38.30 | 78.82 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 4,155 | 19,814 | 20.97 | |
| 125,237 | 344,052 | 36.40 | |
| 52,193 | 128,661 | 40.57 | |
| 1,031 | 4,565 | 22.58 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| BCTX – BriaCell Therapeutics Corp. | BFRG – Bullfrog AI Holdings, Inc. |
| BFRI – Biofrontera Inc. | BIVI – BioVie Inc. |
| BMRA – Biomerica, Inc. |
Financial data and stock pages provided by
Fintel.io